Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials
Participants who continued or switched to DOR generally had comparable efficacy and safety outcomes across sex and race subgroups. However, the sample size was limited. Future studies should ensure greater diversity when investigating factors leading to outcome disparities. <b>ClinicalTrials.gov:</b> NCT02275780, NCT02403674, NCT02397096.
Authors
- Sharon Walmsley (ORCID: https://orcid.org/0000-0002-3959-5692)
- Y. Omar Whiteside (ORCID: https://orcid.org/0000-0002-7828-3018)
- Chloe Orkin (ORCID: https://orcid.org/0000-0001-6168-6745)
- Rima Lahoulou
- Rebeca M. Plank (ORCID: https://orcid.org/0009-0009-4976-0792)
- Zhi Jin Xu (ORCID: https://orcid.org/0000-0002-5916-1605)
- Melanie Thompson (ORCID: https://orcid.org/0009-0005-0341-2400)
- Princy Kumar (ORCID: https://orcid.org/0000-0002-5994-2727)
- Wayne L. Greaves
- Kathleen Squires
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- IDEXX Laboratories (France) (FR)
- University Health Network (CA)
- Queen Mary University of London (GB)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- Thomas University (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1093/ofid/ofaf356
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Merck
- Merck Sharp and Dohme